Tokyo court dismisses Genentech patent suit against Sandoz
04-06-2019
Genentech enters agreement to develop autoimmune therapies
21-05-2019
hafakot / Shutterstock.com
US-based biotechnology company Genentech, a subsidiary of Roche, has entered into a settlement agreement with Samsung Bioepis, ending all patent litigation between the two companies.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Genentech, Samsung Bioepis, patent infringement, trastuzumab, Herceptin, Ontruzant, biosimilar
